Tipsheet
What matters at India’s listed companies
Earnings · Chemicals · Small cap

Camlin Fine Sciences cuts standalone losses, but revenue also shrank

Standalone net loss narrowed sharply in FY26, but the improvement came from lower revenue, not growth. Consolidated profit was a one-off from a European liquidation.

3 earlier stories on Camlin Fine Sciences Ltd.
Mkt cap₹2,619 cr
P/E94.81×
ROE0.00%
Debt / eq.0.72
₹3,296.62 lakh FY26 standalone net loss, down from ₹7,631.05 lakh a year ago.

What's new

  • Standalone net loss narrowed to ₹3,296.62 lakh in FY26 from ₹7,631.05 lakh in the prior year.
  • Standalone revenue declined to ₹83,791.82 lakh from ₹88,649.13 lakh.
  • Consolidated net profit of ₹2,762.72 lakh was driven by a gain from CPS Europe liquidation.

Why this matters

The loss reduction is welcome, but it was achieved on a smaller revenue base, suggesting cost cuts rather than a sales rebound. The consolidated profit is non-recurring, masking the fact that the core standalone operations are still deep in the red.

What we're watching

  • Whether standalone losses continue to narrow in FY27 on an organically growing top line.
  • The rationale behind the simultaneous CFO appointment and re-designation.
  • How consolidated results look once the CPS Europe liquidation gain is no longer a factor.

The full read

Camlin Fine Sciences' FY26 results show a company cutting its standalone losses but not yet growing. The standalone net loss fell to ₹3,296.62 lakh from ₹7,631.05 lakh the year before, a material improvement. But standalone revenue also shrank to ₹83,791.82 lakh from ₹88,649.13 lakh, meaning the better bottom line came from a smaller top line. At the consolidated level, the company posted a profit of ₹2,762.72 lakh. That number, however, is a one-off, driven by a gain from the liquidation of CPS Europe. Strip out that discontinued-operation event and the core business remains loss-making. The board also approved a new CFO and re-designated the existing one, adding a layer of management change to an operational story that is still about managing decline, not reversing it.

Questions answered

How did Camlin's core standalone business perform in FY26?
The standalone net loss narrowed to ₹3,296.62 lakh from ₹7,631.05 lakh in FY25. However, standalone revenue also fell to ₹83,791.82 lakh from ₹88,649.13 lakh, indicating the loss improvement came from tighter spending.
Why was consolidated net profit positive?
Consolidated net profit attributable to owners was ₹2,762.72 lakh, driven almost entirely by a one-time gain from the liquidation of CPS Europe, a discontinued operation. The core business remained unprofitable.
What management changes were announced alongside the results?
The board approved the appointment of a new CFO and simultaneously re-designated the existing CFO to a different role. This signals a restructuring at the top of the finance function.
Is the narrowing standalone loss a sign of recovery?
The loss narrowed by about 57%, which is a significant reduction. But it occurred alongside a revenue decline, suggesting the improvement is from cost management rather than renewed growth in the core business.
Mentioned: CPS Europe liquidation · New CFO appointment · FY2025-26 results
Primary source BSE · NSE · Tijori

An independent reading of the company's own disclosure — the primary filing above is the final word.

Company snapshot

Camlin Fine Sciences Ltd.

Chemicals
₹2,597 cr
P/E 94.01×

Latest quarter · Mar 2026

Sales₹425 cr
Net profit₹85 cr
Op. margin+5.0%
EPS₹4.59

Strength & growth

Debt / equity0.72×
Current ratio1.40×
Sales CAGR+13.6%
EPS CAGR−9.3%
  1. 26 May 2026 · 4:43 PM IST Camlin Fine Sciences cuts standalone losses, but revenue also shrank
  2. 3d ago Camlin Fine's top R&D scientist resigns citing personal commitments
  3. 45d ago Camlin Fine Sciences cuts vanillin price guidance as costs surge
  4. 45d ago Camlin profit on Italian sale masks a still-lossmaking core